Bayer’s Triple Play: A New AI Deal, ASCO Showcase, and a Supreme Court Cliffhanger
Published on 06/24/2026 at 19:55 | Redaktion boerse-global.de
Bayer is threading a needle between scientific promise and a stubborn legal hangover. The Leverkusen-based group has unveiled a research collaboration with US biotech Iambic Therapeutics to supercharge drug discovery using artificial intelligence, while simultaneously presenting 16 new studies at the American Society of Clinical Oncology (ASCO) annual meeting. Yet the euphoria around its pipeline is tempered by a looming Supreme Court ruling and an expected €5 billion cash drain from glyphosate litigation in 2026.
Under the Iambic partnership, Bayer will deploy the biotech’s two AI platforms, Enchant and NeuralPLexer, to identify targets that have historically been difficult to drug. The technology is aimed primarily at oncology, with other therapeutic areas to follow. The goal is to reduce the number of molecules that need to be tested, shorten development timelines, and lower costs. Iambic receives an upfront payment plus undisclosed milestone and royalty fees.
The ASCO data dump adds heft to the pipeline narrative. Bayer highlighted its prostate cancer drug Nubeqa, with the phase II ARACOG study pitting it directly against Enzalutamide. The company also won US Food and Drug Administration approval for the contrast agent Gadoquatrane, while European regulators are reviewing Asundexian, a promising compound that has yet to secure any marketing authorization worldwide.
The bigger catalyst, however, rests with the US Supreme Court. In April 2026, the court heard Monsanto v. Durnell, a case that asks whether pesticide makers can be held liable under state law for warning labels not mandated by the Environmental Protection Agency. A ruling favourable to Bayer could effectively remove the bulk of the more than 100,000 glyphosate lawsuits weighing on the stock. The decision is expected by the end of June, with the next possible announcement as early as Thursday.
Should investors sell immediately? Or is it worth buying Bayer?
Litigation costs continue to gnaw at the balance sheet. Bayer has built substantial provisions for the glyphosate claims and expects cash outflows of roughly €5 billion in 2026 alone. That burden is pinching liquidity, with management forecasting negative free cash flow between €1.5 billion and €2.5 billion for the full year.
On the plus side, the company has chipped away at its debt pile. Net financial debt fell from €32.6 billion at the end of 2024 to €29.8 billion at the end of 2025. Including legal provisions, however, total net debt stands at about €33 billion. Free cash flow was positive at €2.1 billion in 2025, a stark contrast to this year’s projected outflow. Revenue growth is seen at a currency-adjusted maximum of 3%.
Beyond the core pharma business, Bayer is tapping Asian markets for new growth. In India, its subsidiary has relaunched Alka Seltzer with probiotics, positioning the antacid squarely at the ayurvedic self-medication segment. The management sees big potential in that market.
Bayer at a turning point? This analysis reveals what investors need to know now.
The stock has responded to the flurry of news with a mixed but upward bias. Shares recently climbed 3.38% to €39.80, while a separate session saw a 2.86% rise to €39.60. Over the past 12 months, the share price has nearly doubled from the August 2025 trough of €25.09. The February high of €49.93 – also the 52-week peak – still sits about 20% above current levels.
Chart technicians have taken notice: the stock now trades nearly 9% above its 200-day moving average, a bullish configuration. The relative strength index at 64.3 points to continued upward momentum without entering overbought territory. Yet a lasting re-rating will hinge on clinical progress – and a green light from Washington.
Ad
Bayer Stock: New Analysis - 24 June
Fresh Bayer information released. What's the impact for investors? Our latest independent report examines recent figures and market trends.
Disclaimer regarding our articles: No investment advice, no buy or sell recommendation. Information on prices, companies, and markets is provided without guarantee; changes are possible at any time. Stock market transactions can lead to substantial losses. Our articles are created and reviewed in whole or in part automatically with the support of AI.
